This supplementary includes the results of the Kaplan-Meier recurrence-free survival analysis for patients enrolled in the study of neoadjuvant taxane-anthracycline chemotherapy in breast cancer (GSE25066). Expression data are represented for TAAR2 and TAAR5 in this dataset. We applied the threshold log2 expression = 5.0 to classify tumor samples as TAAR-positive or TAAR-negative for each TAAR gene expression.

Association of TAARs expression and recurrence-free survival (time in years)